UnifiedACB

Medication evidence profile

Glycopyrrolate

Ask about Glycopyrrolate

Clinical overview

Glycopyrrolate has public medication-list entries in Yamada-ABS 2023, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 5 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARSNot listed
Yamada-ABS2
BAASNot listed
Swe-ABS3
GABS1
KABS2
CALS1

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

Other names used in the sources

Glycopyrronium, Glycopyrronium (injection), Glycopyrronium inhalative, glycopyrrolate * †, glycopyrronium inhaled * †

How to interpret the evidence

5 of 7 public source versions contain an explicit medication-list entry for glycopyrrolate.

The recorded values differ across the source rows for glycopyrrolate. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.

Source labels and provenance · 5 observations
  1. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: Glycopyrronium. Published value: 2.
    Source version: YAMADA-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: YAMADA_ABS_2023_R0045; rating state: published_rating.

  2. Swedish Anticholinergic Burden Scale 2023

    Source label: Glycopyrronium (injection). Published value: 3.
    Source version: SWE-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_final_nonzero_complete
    Observation: SWE_ABS_2023_R0093; rating state: published_rating.

  3. German Anticholinergic Burden Score 2018

    Source label: Glycopyrronium inhalative. Published value: 1.
    Source version: GABS-2018
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: GABS_2018_R0049; rating state: published_rating.

  4. KABS 2019 scale - 2020 open validation supplement

    Source label: Glycopyrrolate. Published value: 2.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Drugs for gastrointestinal conditions and disorders; table row 68
    Observation: KABS2020_SUPP_0353; rating state: published_validation_supplement_rating.

  5. CALS 2022 - primary final Table 4

    Source label: Glycopyrronium. Published value: 1.
    Source version: CALS-2022-primary-table4
    Source location: Table 4; literal capture row 177; displayed table row 26; displayed column 2
    Observation: CALS2022_T4_0177; rating state: published_final_table_rating.

Dose, route, and formulation notes

Swe-ABS 2023 uses the source label “Glycopyrronium (injection)”. This qualification remains attached to that row. SWE-ABS-2023

GABS 2018 uses the source label “Glycopyrronium inhalative”. This qualification remains attached to that row. GABS-2018

Glycopyrrolate/glycopyrronium reviewed as a naming/active-moiety identity cluster. CALS specifies inhaled glycopyrronium; other sources may represent different formulations. Source scores must remain separate.

What this page does not establish

  • No medication-list entry is available here from JARS 2025 and BAAS 2019. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • Formulation-sensitive cluster: canonical search grouping does not make routes or formulations interchangeable.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  2. Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
  3. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
  4. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
  5. Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Glycopyrrolate

Ask about this medication
Show Glycopyrrolate across all available scalesWhy do the scales differ for Glycopyrrolate?Show the evidence for GlycopyrrolateCompare Glycopyrrolate with another medication